Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician-Reference-Cited by-同舟云学术

Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician

Published:2019-01 Issue: Volume:13 Page:117954681986644
ISSN:1179-5468
Container-title:Clinical Medicine Insights: Cardiology
language:en
Short-container-title:Clin Med Insights Cardiol

Author:

Perez Irving E¹^ORCID,Taveras Alam Sara²,Hernandez Gabriel A¹,Sancassani Rhea¹

Affiliation:

1. Department of Cardiovascular Disease, Jackson Memorial Hospital, University of Miami Hospital, Miami, FL, USA

2. Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

Abstract

Cancer therapy-related cardiac dysfunction (CTRCD) is one of the most feared and undesirable side effects of chemotherapy, occurring in approximately 10% of the patients. It can be classified as direct (dose-dependent vs dose-independent) or indirect, either case being potentially permanent or reversible. Risk assessment, recognition, and prevention of CTRCD are crucial.

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1179546819866445

Reference104 articles.

1. Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care

2. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

3. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

4. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

5. Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding Cardiac Events in Breast Cancer (UCARE) - Pilot Cardio-Oncology Assessment and Surveillance Pathway for Breast Cancer Patients;2023-12-17

2. Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines;Journal of Personalized Medicine;2023-12-14

3. Assessment of doxorubicin toxicity using human cardiac organoids: A novel model for evaluating drug cardiotoxicity;Chemico-Biological Interactions;2023-12

4. Sorting nexin 3 exacerbates doxorubicin-induced cardiomyopathy via regulation of TFRC-dependent ferroptosis;Acta Pharmaceutica Sinica B;2023-12

5. Preventing new-onset heart failure: Intervening at stage A;American Journal of Preventive Cardiology;2023-12